Gilead eases HIV supply chain fears as COVID-19 manufacturing concerns mount

Gilead on Sunday said it would hold emergency access to COVID-19 candidate remdesivir. (Gilead)

Fearing shortages of COVID-19 hopeful remdesivir, Gilead Sciences has mostly shut the tap for the antiviral candidate as it cycles through clinical trials. But shortages won't be hitting its other drugs, it reassured the public Tuesday.

Gilead touted its "robust and resilient" supply chain with "the right processes in place, geographic diversity in our supply chain and enough of the materials required to make our medicines" in a statement Tuesday. 

The drugmaker hasn't seen any scarcity for any of its marketed drugs—including its approved HIV portfolio—so far during the novel coronavirus crisis and does not anticipate any shortages in the future, it said. Gilead markets the HIV blockbusters Biktarvy, Descovy, Truvada, Genvoya and Odefsey. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

"We are contributing our antiviral expertise and resources to help communities respond to the novel coronavirus outbreak and can assure our partners, healthcare providers, and the people we serve that our medications will continue to be available," Gilead said. 

RELATED: Gilead halts emergency access to COVID-19 contender remdesivir amid 'overwhelming demand'

Gilead said it would stop granting patients emergency access to remdesivir under compassionate use due to an “exponential increase” in requests over the last few days. Exceptions will be made to pregnant women and children under 18 with severe COVID-19, the disease caused by the novel coronavirus.

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.